Christoph Hüls, PhD, Head of Technology Foresight & Scouting.
Christoph Hüls (born 1962) is Head of Technology Foresight & Scouting at Merck KGaA, Darmstadt, Germany. In his role he is responsible for developing an innovation strategy and the first steps of its implementation towards new business for Merck. Previously he held different positions in the Chemical as well as the Healthcare sectors of Merck in new business development, licensing, corporate venture capital and operational excellence in R&D. Prior to Merck, Christoph was chairmen of the Board of Protagen AG a German biotech company active in development of software and services for the life science industry as well as diagnostics. Before that, Christoph was responsible for portfolio and project management within the generics division of Novartis. Christoph began his professional career at Hoechst AG in different responsibilities in pharmaceutical and chemical R&D. He studied Biology and received his PhD from the Johannes-Gutenberg University in Mainz at the Institute of Immunology.
Larger corporations face the problem not knowing what their technology base really is. The portfolio management decisions are therefore based on “gut feeling” of the senior people in the organization. The application of digital solutions and machine learning can enable better overview of the technology landscape of large global organizations and facilitate collaboration across business sectors and geographies. It can automate data collection and generate a software solution that connects the technology platforms to e.g. finance, market, literature and patent data. The presentation will showcase how Merck has implemented a solution enabling R&D to better and faster deliver on projects, scouts to find the right experts to evaluate technologies and strategists to make better decisions. And ultimately to make technology platform management data based.View Details